Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Zai Lab Acquires China Rights to Novel Antibiotic from Paratek

publication date: Apr 24, 2017
Shanghai's Zai Lab acquired Greater China rights to omadacycline, an antibiotic for drug-resistant infections, from Paratek Pharma of Boston. Zai will make a $7.5 million upfront payment plus pay development, regulatory and commercial milestones and royalties. The antibiotic is Zai Lab's eighth in-licensed product: the company is developing four cancer candidates, two anti-inflammatory products, a treatment for eczema and now an antibiotic. Zai also recently partnered with GE Healthcare to build a biomanufacturing plant in Suzhou. More details...

Stock Symbol: (NSDQ: PRTK)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here